Multivariable model of risk factors associated with Lipoatrophy.

<p>Multivariable model of risk factors associated with Lipoatrophy.</p

Multivariable model of risk factors associated with Lipohypertrophy.

<p>Multivariable model of risk factors associated with Lipohypertrophy.</p

Description of cases of lipoatrophy (LA) and lipohypertrophy (LH) compared to non-cases.

<p>Description of cases of lipoatrophy (LA) and lipohypertrophy (LH) compared to non-cases.</p

Kaplan-Meier of emergence of LA or LH in children on ART in the UK and Ireland.

<p>Kaplan-Meier of emergence of LA or LH in children on ART in the UK and Ireland.</p

Prevalence of lipoatrophy (LA) and lipohypertrophy (LH) and proportion of children on stavudine and on protease inhibitors during each calendar year in the UK and Ireland.

<p>The denominator for calculation of prevalence in each calendar year is presented below the graph.</p

Cognitive performance by domain and HIV/CDC status.

Data points are means with 95% confidence intervals. P-values compare the three groups (HIV, PHIV/no C, PHIV/C) using analysis of variance. Abbreviations: CDC, Centers for Disease Control and Prevention, HIV-, HIV negative; PHIV, perinatal HIV; PHIV/C, PHIV with a CDC C diagnosis; PHIV/no C, PHIV without a CDC C diagnosis.</p

Additional file 1: of Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project

Characteristics at cART initiation according to presence/absence of PDR. Table. (DOCX 20 kb

Additional file 2: of Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project

Crude Hazard Ratios (cHR) and adjusted Hazard Ratios (aHR) for the association between PDR and resistant group versus no PDR/susceptible group from Cox proportional Hazards models stratified by initial cART regimen. HR in the overall group are also presented in more details in Table 3 of the article. All models were adjusted for sex, age, pre-treatment viral load (log10 transformed) and CD4 count, subtype, region of origin, year of treatment start, previous AIDS diagnosis and HIV transmission risk group. (DOCX 46 kb

Characteristics of children overall, and by timing of death, for those who died.

<p>Characteristics of children overall, and by timing of death, for those who died.</p

Causes of death for children who died, overall, and by timing of death.

<p>Causes of death for children who died, overall, and by timing of death.</p